|
Garcia-Torralba E, Navarro Manzano E, Luengo-Gil G, De la Morena Barrio P, Chaves Benito A, Perez-Ramos M, Alvarez-Abril B, Ivars Rubio A, Garcia-Garre E, Ayala de la Pena F, Garcia-Martinez E. A new prognostic model including immune biomarkers, genomic proliferation tumor markers (AURKA and MYBL2) and clinical-pathological features optimizes prognosis in neoadjuvant breast cancer patients. Front Oncol. 2023 May 29;13:1182725. doi: 10.3389/fonc.2023.1182725. eCollection 2023. PubMed PMID: 37313470; PubMed Central PMCID: PMC10258327.
AÑO: 2023; IF: 3.5
|
37313470
|
Bueno-Muino C, Echavarria I, Lopez-Tarruella S, Roche-Molina M, Del Monte-Millan M, Massarrah T, Jerez Y, Ayala de la Pena F, Garcia-Saenz JA, Moreno F, Rodriguez-Lescure A, Malon-Gimenez D, Ballesteros Garcia AI, Marin-Aguilera M, Galvan P, Braso-Maristany F, Waks AG, Tolaney SM, Mittendorf EA, Vivancos A, Villagrasa P, Parker JS, Perou CM, Pare L, Villacampa G, Prat A, Martin M. Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab. JAMA Oncol. 2023 Jun 1;9(6):841-846. doi: 10.1001/jamaoncol.2023.0187. PubMed PMID: 37103916; PubMed Central PMCID: PMC10141274.
AÑO: 2023; IF: 22.5
|
|
Garcia-Torralba E, Perez Ramos M, Ivars Rubio A, Navarro-Manzano E, Blaya Boluda N, de la Morena Barrio P, Garcia-Garre E, Martinez Diaz F, Chaves-Benito A, Garcia-Martinez E, Ayala de la Pena F. Clinical Meaning of Stromal Tumor Infiltrating Lymphocytes (sTIL) in Early Luminal B Breast Cancer. Cancers (Basel). 2023 May 20;15(10):2846. doi: 10.3390/cancers15102846. PubMed PMID: 37345183; PubMed Central PMCID: PMC10216816.
AÑO: 2023; IF: 4.5
|
|
Vicente Conesa MA, Zafra Poves M, Carmona-Bayonas A, Ballester Navarro I, de la Morena Barrio P, Ivars Rubio A, Montenegro Luis S, Garcia Garre E, Vicente V, Ayala de la Pena F. A prognostic model to identify short survival expectancy of medical oncology patients at the time of hospital discharge. ESMO Open. 2022 Feb;7(1):100384. doi: 10.1016/j.esmoop.2022.100384. Epub 2022 Feb 7. PubMed PMID: 35144121; PubMed Central PMCID: PMC8844687.
AÑO: 2022; IF: 6.883
|
|
Castillo-Guardiola V, Rosado-Jimenez L, Sarabia-Meseguer MD, Marin-Vera M, Macias-Cerrolaza JA, Garcia-Hernandez R, Zafra-Poves M, Sanchez-Henarejos P, Moreno-Locubiche MA, Cuevas-Tortosa E, Arnaldos-Carrillo M, Ayala de la Pena F, Alonso-Romero JL, Noguera-Velasco JA, Ruiz-Espejo F. Next step in molecular genetics of hereditary breast/ovarian cancer: Multigene panel testing in clinical actionably genes and prioritization algorithms in the study of variants of uncertain significance. Eur J Med Genet. 2022 Apr;65(4):104468. doi: 10.1016/j.ejmg.2022.104468. Epub 2022 Mar 1. PubMed PMID: 35245693.
AÑO: 2022; IF: 1.9
|